Ogden Regional Medical Center Standardizes to Masimo rainbow® Pulse CO-Oximetry™ Leading-Edge Utah Hospital Leverages Advanced Medical Technologies for Noninvasive, Continuous Patient Monitoring, Including Total Hemoglobin (SpHb®)
IRVINE, Calif., Dec. 19, 2012 /PRNewswire/ -- Masimo (NASDAQ: MASI) today announced that Ogden Regional Medical Center (ORMC), named by The Joint Commission as a Top Performer on Key Quality Measures™, has standardized to Masimo rainbow® Pulse CO-Oximetry™ and sensor technologies for advanced patient monitoring. This noninvasive technology helps save lives by making it safer, faster, and easier than ever for healthcare professionals to measure and monitor patient conditions – on-the-spot, in just seconds.
The conversion equips Ogden Regional Medical Center with breakthrough rainbow® technology. Among its multiple capabilities, this innovation enables needleless and pain-free blood testing of total hemoglobin (SpHb®) – and delivers immediate results for hospital patients.
"I like the fact that you can pinpoint the total hemoglobin in real time, and quickly identify a patient's status on a waveform display; both of these features make my job more manageable," said Travis Slade, MD, an anesthesiologist at ORMC. "I've also been very impressed with the device's sensitivity. It consistently displays results that are nearly identical to (hemoglobin) lab tests we've run. It also works when other technologies don't. There have been cases when we used a conventional pulse ox that didn't produce a SpO2 reading. We brought in the Masimo, and got the results we needed."
Other Masimo rainbow® measurements in use at ORMC include SpCO®, which helps clinicians to more quickly detect elevated levels of carbon monoxide in the blood – which can facilitate earlier diagnosis and treatment for patients poisoned by carbon monoxide; and Pleth Variability Index (PVI®), which can continuously assess and allow clinicians to better manage fluids as they are administered to patients – in a noninvasive and cost-effective manner.
As part of its system-wide conversion, ORMC will also leverage Masimo SET® pulse oximetry in every patient care setting. A standard-of-care at leading hospitals worldwide, Masimo SET® has been clinically shown to virtually eliminate false alarms1 and increase a clinician's ability to detect life-threatening events.2
"We are thrilled that ORMC, with its nationally recognized reputation for quality of care, has selected Masimo SET® and Masimo rainbow® technologies as key parts of its ongoing commitment to patient safety," said Masimo CEO and founder Joe Kiani. "It is an honor to be able to partner with such an esteemed healthcare organization, and we look forward to working with ORMC for years to come."
1 Shah N, Ragaswamy H, Govindugari K, Estanol L. "Performance of three new-generation pulse oximeters during motion and low perfusion in volunteers." Journal of Clinical Anesthesia. 2012 (10.1016/j.jclinane.2011.10.012) Available online here
2 Taenzer, Andreas H.; Pyke, Joshua B.; McGrath, Susan P.; Blike, George T. "Impact of Pulse Oximetry Surveillance on Rescue Events and Intensive Care Unit Transfers: A Before-and-After Concurrence Study." Anesthesiology, February 2010, Vol. 112, Issue 2. Available online here
About Ogden Regional Medical Center
This MountainStar Healthcare hospital utilizes advanced technologies while delivering nationally recognized care to patients in northern Utah and surrounding communities. It was recently honored with the 2012 100 Top Hospitals® Award in the category of medium-sized community hospitals and recognized as a 2011 Top Performer on Key Quality Measures™ for heart attack care, pneumonia and surgical care by The Joint Commission. It is one of only three in Utah to achieve the 2012 and 2011 Maternity Care Excellence Award from HealthGrades, a national healthcare rating organization, which also recognized the hospital among the top fifteen percent in the country for treating COPD and sepsis. As a Level II Trauma Center and a Certified Stroke Center, ORMC was ranked among the top 15 percent in the nation for stroke treatment in 2011 by HealthGrades.
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care—helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies have shown that Masimo SET® outperforms other pulse oximetry technologies, even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow SET® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb®), oxygen content (SpOCTM), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). In 2008, Masimo introduced Patient SafetyNet™, a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events. In 2009, Masimo introduced rainbow® Acoustic MonitoringTM, the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa™). Masimo's rainbow® SET® technology platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options. In 2010, Masimo acquired SedLine®, a pioneer in the development of innovative brain function monitoring technology and devices. In 2012, Masimo acquired assets of Spire Semiconductor, LLC, maker of advanced light emitting diode (LED) and other advanced component-level technologies; and acquired Phasein AB, a developer and manufacturer of ultra-compact mainstream and sidestream capnography, multigas analyzers, and handheld capnometry solutions. Masimo SET® and Masimo rainbow® SET® technologies also can be found in over 100 multiparameter patient monitors from over 50 medical device manufacturers around the world. Founded in 1989, Masimo has the mission of "Improving Patient Outcome and Reducing Cost of Care … by Taking Noninvasive Monitoring to New Sites and Applications®." Additional information about Masimo and its products may be found at www.masimo.com.
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including: total hemoglobin (SpHb), SpOC, SpCO, SpMet, and PVI contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions with comparable accuracy and unique advantages, including: immediate and continuous results that enable earlier treatment without causing invasive trauma in all patients and in every clinical situation; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57,Rad-8, Rad-5,Pulse CO-Oximetry, Pulse CO-Oximeter, Adaptive Threshold Alarm, and SEDLine are trademarks or registered trademarks of Masimo Corporation. The use of the trademarks Patient SafetyNet and PSN is under license from University HealthSystem Consortium.